Abstract | BACKGROUND: MATERIALS AND METHODS: It was a randomized, crossover, controlled clinical trial. Women with breast cancer and scheduled to receive AC regimens were enrolled in this study. Enrolled patients were randomized into two groups. Group I received 3 days regimen of aprepitant in the first course of AC regimen chemotherapy and 6 days regimen of aprepitant in the second course; Group II received 6 days regimen followed by 3 days regimen. For nausea and vomiting assessment, we used Eastern Cooperative Oncology Group questionnaire. RESULTS: Forty-nine patients were enrolled in this study. Sixty-three percent achieved a complete response with 6 days aprepitant regimen compared with 39% with 3 days regimen (P < 0.001). Ten percent had at least one vomiting episode during the 6 days regimen versus 15% with 3 days regimen (P = 0.034). Nausea was significantly more severe in 3 days regimen of aprepitant than in 6 days regimen. CONCLUSION: Increase in the duration of aprepitant consumption through 6 days resulted in significantly better prevention of nausea and vomiting than 3 days consumption for women receiving AC chemotherapy.
|
Authors | Negah Chaabi Ahvazi, Simin Hemati, Mohamad Mohamadianpanah |
Journal | Advanced biomedical research
(Adv Biomed Res)
Vol. 4
Pg. 238
( 2015)
ISSN: 2277-9175 [Print] India |
PMID | 26682204
(Publication Type: Journal Article)
|